newsfilter
← Latest News
GlobeNewswire·

Celsion and Medidata to Present Findings on Use of Synthetic Control Arm to Estimate Treatment Effect in Ovarian Cancer Trial

Phase Ib dose-escalating OVATION I Study with GEN-1 in advanced ovarian cancer patients to be presented at 2022 AACR Annual Meeting being held April 8-13 in New Orleans, LA LAWRENCEVILLE, N.J., April 06, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation